Back

Activity of piperacillintazobactam and comparators against Pseudomonas aeruginosa and Acinetobacter baumannii from South Africa, 20042009

Abstract number: P783

Background: Piperacillin–tazobactam (PTZ) continues to be useful for the treatment of patients with polymicrobial infections caused by aerobic or anaerobic b-lactamase-producing bacteria. PTZ is indicated for severe community and hospital acquired infections including Pseudomonas aeruginosa as well as Acinetobacter baumannii. In the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), a comprehensive global surveillance study, we have monitored the in vitro activity of PTZ and comparators for 6 years.

Methods: We evaluated 435 A. baumannii (183) and P. aeruginosa (252) isolates from 21 cumulative sites in South Africa between 2004 and 2009. Isolates were identified at each study site and confirmed by the central lab following CLSI guidelines.

Results: The table shows MIC90 and % susceptible of PTZ and comparators against P. aeruginosa and A. baumannii.

Conclusions: Since the approval of PTZ in 1993, PTZ continues to demonstrate potent in vitro activity against P. aeruginosa. The activity of PTZ is comparable to that of amikacin, imipenem and meropenem. Only tigecycline demonstrated significant activity against A. baumannii with MIC90 values more than 8- to 128-fold lower than any other study drug.

 P. aeruginosa (n = 252)A. baumannii (n = 183)
 MIC90%SMIC90%S
Piperacillin–Tazobactam12888>12828
Amikacin6485>6438
Cefepime3277>3224
Ceftazidime1684>3224
Ceftriaxone>6415>6415
Imipenem886>1668
Meropenem>1680>1624
Levofloxacin>864>832
Tigecycline>16na1na

Session Details

Date: 10/04/2010
Time: 00:00-00:00
Session name: Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases
Subject:
Location: Vienna, Austria, 10 - 13 April 2010
Presentation type:
Back to top